|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1201 F STREET, NW, #480 |
Address2 |
|
| City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 16293-12
|
||||||||
|
6. House ID# 314610000
|
||||||||
| TYPE OF REPORT | 8. Year | 2024 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Michael J. Calvo |
Date | 4/22/2024 8:07:11 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
H.R. 4368: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024
H.R. 5894: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024
H.R. 2670: National Defense Authorization Act for Fiscal Year 2024 (P.L. 118-31)
S. 2226: National Defense Authorization Act for Fiscal Year 2024
S. 2131: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024
S. 2624: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024
FY 2025 President's Budget Request
Inflation Reduction Act of 2022 (P.L. 117-169)
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (P.L. 117-180)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Calvo |
|
|
|
Philip |
Thevenet |
|
|
|
Curtis |
Rhyne |
|
|
|
Amy |
Efantis |
|
|
|
Monica |
Cloud |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
H.R. 1717: Interagency Patent Coordination and Improvement Act of 2023
H.R. 4370: PREVAIL Act - Provisions related to the PTAB
H.R. 4692: Increasing Prescription Drug Competition Act - Patent-related policy issues
H.R. 5429: Medication Affordability and Patent Integrity Act
H.R. 5475: Prohibiting Adversarial Patents Act of 2023
H.R. 6275: Protecting Consumer Access to Generic Drugs Act of 2023 - Patent-related policy issues
H.R. 6436: Stopping Pharmas Ripoffs and Drug Savings For All Act - Patent-related policy issues
H.R. 6684: Improving Efficiency to Increase Competition Act - Patent-related policy issues
H.R. 6986: To address patent thickets - Provisions related to patents
S. 79: Interagency Patent Coordination and Improvement Act of 2023
S. 142: Preserve Access to Affordable Generics and Biosimilars Act - Provisions related to patent settlements
S. 150: Affordable Prescriptions for Patients Act of 2023 - Provisions related to intellectual property and patents
S. 574: Increasing Prescription Drug Competition Act - Patent-related policy issues
S. 2140: Patent Eligibility Restoration Act of 2023 - Provisions related to patents
S. 2220: PREVAIL Act - Provisions related to the PTAB
S. 2780: Medication Affordability and Patent Integrity Act
S. 3583: A bill to address patent thickets - Provisions related to patents
Biopharmaceutical innovation and patent policy issues
Bayh-Dole march-in rights policy issues
Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights (Docket No.: 230831-0207)
Patent thicket policy issues
Patent use codes policy issues
AI patent policy issues
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Calvo |
|
|
|
Philip |
Thevenet |
|
|
|
Curtis |
Rhyne |
|
|
|
Amy |
Efantis |
|
|
|
Monica |
Cloud |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 167: Patient Access to Urgent-Use Pharmacy Compounding Act of 2023
H.R. 198: Drug Pricing Transparency and Accountability Act - Provisions related to the 340B Program
H.R. 830: HELP Copays Act - To amend title XXVII of the Public Health Service Act to apply additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes
H.R. 885: TRACK Act of 2023
H.R. 1503: Prescription Information Modernization Act of 2023
H.R. 1613: Drug Price Transparency in Medicaid Act of 2023
H.R. 1790: Biologics Competition Act of 2023 - To direct the Secretary of Health and Human Services to evaluate the extent to which the substitution of interchangeable biological products is impacted by differences between the system for determining a biological product to be interchangeable and the system for assigning therapeutic equivalence ratings to drugs, and for other purposes
H.R. 2408: Access to Innovative Treatments Act of 2023
H.R. 2500: Protecting Americans from Unsafe Drugs Act of 2023
H.R. 2534: PROTECT 340B Act of 2023 - Provisions related to the 340B program
H.R. 2679: Pharmacy Benefits Manager Accountability Act
H.R. 2707: MADE in America Act
H.R. 2816: Pharmacy Benefit Manager Sunshine and Accountability Act
H.R. 2880: Protecting Patients Against PBM Abuses Act
H.R. 2893: Seniors Securing Access to Vital and Essential Prescription Drugs Act
H.R. 2959: Health Savings Act of 2023
H.R. 3008: Drug Shortage Prevention Act of 2023
H.R. 3093: Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2023
H.R. 3285: Fairness for Patient Medications Act
H.R. 3290: To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program
H.R. 3433: Give Kids a Chance Act of 2023
H.R. 3561: Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or PATIENT Act of 2023
H.R. 3839: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications
H.R. 4115: Lower Drug Costs for Families Act
H.R. 4263: Allergen Disclosure in Non-food Articles Act (ADINA)
H.R. 4421: Preparing for All Hazards and Pathogens Reauthorization Act
H.R. 4895: Lowering Drug Costs for American Families Act - Provisions related to drug pricing
H.R. 4988: Modern Authentication of Pharmaceuticals Act of 2023
H.R. 5376: Share the Savings with Seniors Act
H.R. 5378: Lower Costs, More Transparency Act
H.R. 5391: Protecting Patient Access to Cancer and Complex Therapies Act
H.R. 5539: ORPHAN Cures Act
H.R. 5547: Maintaining Investments in New Innovation Act
H.R. 6283: Delinking Revenue from Unfair Gouging or DRUG Act
H.R. 6664: Innovation in Pediatric Drugs Act of 2023
H.R. 7174: Ensuring Pathways to Innovative Cures (EPIC) Act: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program
H.R. 7248: FDA Modernization Act 3.0
S. 113: Prescription Pricing for the People Act of 2023 - Provisions related to PBMs
S. 127: Pharmacy Benefit Manager Transparency Act of 2023 - Provisions related to PBMs
S. 148: Stop STALLING Act - Provisions related to citizen petitions
S. 775: Increasing Transparency in Generic Drug Applications Act
S. 935: Fair Accountability and Innovative Research Drug Pricing Act of 2023 - Provisions related to drug pricing
S. 1067: Ensuring Timely Access to Generics Act of 2023
S. 1114: Expanding Access to Low-Cost Generics Act 2023
S. 1130: Health Care PRICE Transparency Act
S. 1128: Ensuring Access to Generic Medications Act
S. 1214: RARE Act - To set forth limitations on exclusive approval or licensure of drugs designated for rare diseases or conditions
S. 1250: Drug-price Transparency for Consumers Act of 2023
S. 1264: SMART Prices Act - Provisions related to drug pricing reform
S. 1339: Pharmacy Benefit Manager Reform Act - Provisions related to PBMs
S. 1355: PASTEUR Act of 2023 - Provisions related to antimicrobial resistance policy issues
S. 1375: HELP Copays Act - To amend title XXVII of the Public Health Service Act to apply additional payments, discounts, and other financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes
S. 1476: Pharmaceutical Research Transparency Act of 2023
S. 1542: Delinking Revenue from Unfair Gouging Act or DRUG Act - Provisions related to PBMs
S. 1589: Safeguarding Patients and Taxpayers Act
S. 1906: Promising Pathway Act - Approval pathway policy issues
S. 1967: PBM Act
S. 2305: Biosimilar Red Tape Elimination Act
S. 2333: Pandemic and All-Hazards Preparedness and Response Act
S. 2456: Protecting Seniors from High Drug Costs Act
S. 2474: Share the Savings with Seniors Act
S. 2973: Modernizing and Ensuring PBM Accountability Act (MEPA)
S. 3393: SUPPORT for Patients and Communities Reauthorization Act
S. 4953: Protect Drug Innovation Act
Executive Order of February 28, 2024, Preventing Access to Americans' Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern__
Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft)
User fee policy issues
Inflation Reduction Act of 2022 (P.L. 117-169)
Pharmacy Benefit Manager reform and policy issues
Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA)
Cancer Moonshot Initiative
21st Century Cures 2.0
Drug cost and pricing policy issues
Principles for drug pricing reform
Drug importation policy issues
Accelerated approval policy issues
FDA regulatory approval authority policy issues
Competition policy issues
Antimicrobial resistance (AMR) policy issues
Supply chain policy issues
Real world evidence policy issues
Clinical trial diversity policy issues
340B drug discount program policy issues
Patient assistance program policy issues
Biosimilar approval and reimbursement policy issues
Drug shortages policy issues
COVID-19 policy issues
Pandemic preparedness policy issues
Cybersecurity policy issues
Artificial intelligence policy issues
H.R.7024 - Tax Relief for American Families and Workers Act of 2024
Vaccine provisions of the Inflation Reduction Act
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Calvo |
|
|
|
Philip |
Thevenet |
|
|
|
Curtis |
Rhyne |
|
|
|
Monica |
Cloud |
|
|
|
Amy |
Efantis |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 133: MERIT Act
H.R. 485: Protecting Health Care for All Patients Act of 2023 - To amend title XI of the Social Security Act to prohibit the use of quality-adjusted life years and similar measures in coverage and payment determinations under Federal health care programs
H.R. 2666: Medicaid VBPs for Patients Act or MVP Act
H.R. 3421: Medicare for All Act
S. 1450: Cutting Medicare Prescription Drugs in Half Act
Inflation Reduction Act of 2022 (P.L. 117-169)
Part D redesign and policy issues including non-interference and rebates policy issues
Part B policy issues
Drug cost and pricing policy issues
Rebate policy issues
Value-based purchasing arrangements policy issues
Center for Medicare and Medicaid Innovation (CMMI) and model policy issues
CMMI Cell and Gene Therapy Access Model
Medicaid rebates and waiver policy issues
CMS Guidance on the Medicare Drug Price Negotiation Program: Initial Memorandum [ ] ___ IPAY 2026 and Solicitation of Comments
CMS Medicare Drug Price Negotiation Revised Guidance
CMS Guidance on Medicare Part B and D Inflation Rebates
Medicaid Drug Rebate Program Proposed rule (CMS-2434-P)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Calvo |
|
|
|
Philip |
Thevenet |
|
|
|
Curtis |
Rhyne |
|
|
|
Amy |
Efantis |
|
|
|
Monica |
Cloud |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
H.R. 405: Essential Medicines Strategic Stockpile Act of 2023
H.R. 4307: Medical Supply Chain Resiliency Act
H.R. 3858: No Free TRIPS Act
H.R. 7085: BIOSECURE Act
S. 845: Short on Competition Act
S. 1834: No Free TRIPS Act
S. 2115: Medical Supply Chain Resiliency Act
S. 3558: BIOSECURE Act
Biopharmaceutical innovation policy issues
International intellectual property and market access policy issues
Pricing and reimbursement policy issues
Supply chain policy issues
WTO TRIPS waiver policy issues
China outbound investment policy issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Calvo |
|
|
|
Philip |
Thevenet |
|
|
|
Curtis |
Rhyne |
|
|
|
Amy |
Efantis |
|
|
|
Monica |
Cloud |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |